Health care startups in Jiangsu, China
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Weikaier Pharmaceutical Technology | Nanjing | Series C | $29.6M | 2026-06-02 |
| Kossel Medical | Suzhou | Series C | $59.5M | 2026-09-01 |
| D3 Bio | Wuxi Shi | Series B | $108.0M | 2025-12-09 |
| HemaCell | Suzhou | Series B | $14.8M | 2026-06-02 |
| Hope Medicine | Nanjing | Series B | $18.5M | 2024-09-27 |
| iCamumo | Suzhou | Series A | $14.4M | 2026-03-09 |
| AccuPulse | Suzhou | Series B | $14.5M | 2026-03-13 |
| Yuce Biotechnology | Suzhou | Series B | $7.4M | 2026-08-31 |
8 rows of the CSV in 5 of its 18 columns.
- The 421 health care startups in Jiangsu, China have raised $6.1B in total.
- 79 of them closed their most recent round in the last 12 months, $881.4M combined.
- The largest of those rounds is D3 Bio's $108.0M Series B, dated December 2025.
- The most recent is Enorna's $15.0M seed round on 29 October 2026.
- Qiming Venture Partners is an investor in 8 of them, more than any other fund.
- Biotech is the most common other sector, with 195 companies (46%).
- 34% were founded in 2020 or later; the median founding year is 2018.
- The most common team size is 11 to 50 employees (37% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
23 of 421| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Kossel Medical | Kossel Medical develops and manufactures vascular interventional devices and clinical system solutions. | Health care | Suzhou | Series C | $59.5M | 2026-09-01 | $103.0M | Fortune Venture Capital, Suzhou International Development Venture Capital, Ming Bioventures +1 | 501 to 1,000 | 2013 |
| Yuce Biotechnology | Yuce Biotechnology focuses on the industrialization of single-molecule immunodiagnostic technologies. | Biotech | Suzhou | Series B | $7.4M | 2026-08-31 | $22.4M | Puhua Capital, Zhengxuan Investment, BioTrack Capital +2 | 101 to 250 | 2019 |
| Haimai Medical | Haimai Medical develops tissue engineering and regenerative medicine technologies. | Health care | Suzhou | Series A | $14.3M | 2026-06-12 | $14.3M | IDG Capital, Shanghai Biomedical Industrial Equity Investment Fund, Tahoe Venture +1 | 51 to 100 | 2021 |
| Weikaier Pharmaceutical Technology | Weikaier Pharmaceutical Technology conducts drug research, transfers generic drug technology, and produces and sells pharmaceuticals. | Biotech | Nanjing | Series C | $29.6M | 2026-06-02 | $120.4M | SDIC Venture Capital, Dyee Capital, Nanjing Innovation Capital Group +1 | 501 to 1,000 | 2010 |
| HemaCell | HemaCell develops cell therapies that regenerate hematopoietic lineages in vitro through stem cell reprogramming. | Biotech | Suzhou | Series B | $14.8M | 2026-06-02 | $62.0M | Northern Light Venture Capital, CDH Investments, CMB International Capital Corporation | 1 to 10 | 2021 |
| AccuPulse | AccuPulse develops pulsed electric field ablation generators and catheters. | Health care | Suzhou | Series B | $14.5M | 2026-03-13 | $72.5M | BioVenture, Shanghai Biomedical Industrial Equity Investment Fund, Med-Fine Capital +1 | 11 to 50 | 2020 |
| iCamumo | iCamumo develops off-the-shelf, general-purpose cell therapies using iPSCs. | Biotech | Suzhou | Series A | $14.4M | 2026-03-09 | $75.2M | Delian Capital, West Lake Science and Technology Direct Investment Fund, Zhiyi Investment | 51 to 100 | 2021 |
| Tingsheng Technology | Tingsheng Technology develops intracardiac ultrasound (ICE) products. | Health care | Nanjing | Series B | $13.9M | 2026-03-05 | $52.8M | Qiming Venture Partners, Taiyu Investment, Tao Capital +2 | 2017 | |
| Micro-Ray Technology | Micro-Ray Technology supplies X-ray tubes and component solutions for medical imaging equipment such as CT machines. | Biotech | Suzhou | Seed | $14.4M | 2026-01-23 | $14.4M | Suzhou Xiangcheng Financial Holding Group | 11 to 50 | 2021 |
| Junji Gene | Junji Gene provides intelligent gene synthesis labs and localizes raw materials for diagnostic kits. | Artificial intelligence | Suzhou | Series A | $14.2M | 2025-12-15 | $14.2M | Dongfang Jiafu | 51 to 100 | 2021 |
| D3 Bio | D3 Bio develops and registers medicines as a biotechnology company. | Biotech | Wuxi Shi | Series B | $108.0M | 2025-12-09 | $370.0M | Matrix Partners China, Boyu Capital, Medicxi | 1 to 10 | 2020 |
| Kunshi Biotechnology | Kunshi Biotechnology develops drugs with an emphasis on solid tumor cells. | Biotech | Suzhou | Series A | $7.0M | 2025-11-20 | $7.0M | Deshi Capital | 51 to 100 | 2021 |
| IMPACT Therapeutics | IMPACT Therapeutics develops similar drugs to treat cancer. | Biotech | Nanjing | Series D | $34.6M | 2024-11-15 | BioVenture, Lilly Asia Ventures, Decheng Capital +2 | 51 to 100 | 2009 | |
| Hope Medicine | Hope Medicine develops science-driven biopharmaceutical treatments in clinical development. | Health care | Nanjing | Series B | $18.5M | 2024-09-27 | $102.6M | Qiming Venture Partners, Sinovation Ventures, Trustbridge Partners +2 | 1 to 10 | 2018 |
| DK MedTech | DK MedTech manufactures vascular interventional medical device products. | Health care | Suzhou | Series E | $24.5M | 2024-06-21 | $36.2M | Qiming Venture Partners, Legend Capital, Oriza Seed Capital (Oriza Yuandian) +1 | 251 to 500 | 2015 |
| Yidao Biotechnology | Yidao Biotechnology researches and develops vaccines and biomedical products. | Biotech | Suzhou | Series D | $25.2M | 2024-05-09 | Qiming Venture Partners, Northern Light Venture Capital | 2017 | ||
| Tuge Medical Technology | Tuge Medical Technology develops and industrializes 4K endoscopic imaging equipment and digital operating rooms. | Health care | Nanjing | Series B | $27.7M | 2024-04-10 | $27.7M | LongRiver Investments | 101 to 250 | 2018 |
| CureGenetics | CureGenetics develops medicines and molecular diagnostics for cancers and genetic diseases. | Biotech | Suzhou | Series B | $9.0M | 2024-03-28 | Qiming Venture Partners, Oriza Holdings, Qingsong Fund +1 | 51 to 100 | 2016 | |
| Atom Bioscience & Pharmaceutical | Atom Bioscience is a clinical-stage biotechnology company. | Biotech | Suzhou | Series D | $82.1M | 2023-10-16 | Fortune Venture Capital, Oriza Holdings, Kaitai Capital +1 | 11 to 50 | 2012 | |
| Zenshine Pharma | Zenshine Pharma develops small molecule drugs for cancer and autoimmune diseases. | Biotech | Nanjing | Series C | $13.7M | 2023-10-13 | $28.7M | Matrix Partners China, Cybernaut Venture Capital, Kunlun Capital +2 | 11 to 50 | 2018 |
| Onechip Bioelectronics | Onechip Bioelectronics develops biosensor chips and nanomaterials. | Biotech | Zhangjiagang | Series B | $13.7M | 2023-09-28 | Matrix Partners China, Qiming Venture Partners, Xiamen C&D Emerging Industry Equity Investment +1 | 11 to 50 | 2014 | |
| Chamlion | Chamlion provides end-to-end digital dentistry solutions based on 3D printing. | Hardware | Nanjing | Series B | $34.3M | 2023-04-19 | Vertex Ventures China, Zhencheng Capital, 3H Health Investment +1 | 501 to 1,000 | 2017 | |
| Weiyun AI | Weiyun AI combines medical health and artificial intelligence to manufacture clinical dental products. | Artificial intelligence | Nanjing | Series B | $15.2M | 2021-03-30 | AlphaX Partners | 1 to 10 | 2018 |
Table 1. Health care startups in Jiangsu, China: the 23 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 421.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | D3 Bio | D3 Bio develops and registers medicines as a biotechnology company. | Biotech | Wuxi Shi | Series B | $108.0M | 2025-12-09 | $370.0M | Matrix Partners China, Boyu Capital, Medicxi | 1 to 10 | 2020 |
| 2 | Kossel Medical | Kossel Medical develops and manufactures vascular interventional devices and clinical system solutions. | Health care | Suzhou | Series C | $59.5M | 2026-09-01 | $103.0M | Fortune Venture Capital, Suzhou International Development Venture Capital, Ming Bioventures +1 | 501 to 1,000 | 2013 |
| 3 | Weikaier Pharmaceutical Technology | Weikaier Pharmaceutical Technology conducts drug research, transfers generic drug technology, and produces and sells pharmaceuticals. | Biotech | Nanjing | Series C | $29.6M | 2026-06-02 | $120.4M | SDIC Venture Capital, Dyee Capital, Nanjing Innovation Capital Group +1 | 501 to 1,000 | 2010 |
| 4 | HemaCell | HemaCell develops cell therapies that regenerate hematopoietic lineages in vitro through stem cell reprogramming. | Biotech | Suzhou | Series B | $14.8M | 2026-06-02 | $62.0M | Northern Light Venture Capital, CDH Investments, CMB International Capital Corporation | 1 to 10 | 2021 |
| 5 | AccuPulse | AccuPulse develops pulsed electric field ablation generators and catheters. | Health care | Suzhou | Series B | $14.5M | 2026-03-13 | $72.5M | BioVenture, Shanghai Biomedical Industrial Equity Investment Fund, Med-Fine Capital +1 | 11 to 50 | 2020 |
| 6 | iCamumo | iCamumo develops off-the-shelf, general-purpose cell therapies using iPSCs. | Biotech | Suzhou | Series A | $14.4M | 2026-03-09 | $75.2M | Delian Capital, West Lake Science and Technology Direct Investment Fund, Zhiyi Investment | 51 to 100 | 2021 |
| 7 | Micro-Ray Technology | Micro-Ray Technology supplies X-ray tubes and component solutions for medical imaging equipment such as CT machines. | Biotech | Suzhou | Seed | $14.4M | 2026-01-23 | $14.4M | Suzhou Xiangcheng Financial Holding Group | 11 to 50 | 2021 |
| 8 | Haimai Medical | Haimai Medical develops tissue engineering and regenerative medicine technologies. | Health care | Suzhou | Series A | $14.3M | 2026-06-12 | $14.3M | IDG Capital, Shanghai Biomedical Industrial Equity Investment Fund, Tahoe Venture +1 | 51 to 100 | 2021 |
| 9 | Junji Gene | Junji Gene provides intelligent gene synthesis labs and localizes raw materials for diagnostic kits. | Artificial intelligence | Suzhou | Series A | $14.2M | 2025-12-15 | $14.2M | Dongfang Jiafu | 51 to 100 | 2021 |
| 10 | Tingsheng Technology | Tingsheng Technology develops intracardiac ultrasound (ICE) products. | Health care | Nanjing | Series B | $13.9M | 2026-03-05 | $52.8M | Qiming Venture Partners, Taiyu Investment, Tao Capital +2 | 2017 |
Table 2. Health care startups in Jiangsu, China: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 8 | 2% | 1 | Tingsheng Technology |
| 2 | Oriza Holdings | Venture capital firm | Suzhou, China | 5 | 1% | ||
| 3 | BioVenture | Venture capital firm | Suzhou, China | 4 | 1% | 1 | AccuPulse |
| 4 | Matrix Partners China | Venture capital firm | Beijing, China | 3 | 1% | 1 | D3 Bio |
| 5 | Wuxi Capital | Angel group | Wuxi Shi, China | 3 | 1% | ||
| 6 | Puhua Capital | Venture capital firm | Hangzhou, China | 3 | 1% | 1 | Yuce Biotechnology |
| 7 | China Life Private Equity Investment | Private equity firm | Beijing, China | 2 | 0% | 1 | Weikaier Pharmaceutical Technology |
| 8 | Ming Bioventures | Venture capital firm | Suzhou, China | 2 | 0% | 1 | Kossel Medical |
| 9 | Fortune Venture Capital | Venture capital firm | Shenzhen, China | 2 | 0% | 1 | Kossel Medical |
| 10 | Northern Light Venture Capital | Venture capital firm | Beijing, China | 2 | 0% | 1 | HemaCell |
| 11 | Sinovation Ventures | Venture capital firm | Beijing, China | 2 | 0% | ||
| 12 | Shanghai Biomedical Industrial Equity Investment Fund | Venture capital firm | Huangpu, China | 2 | 0% | 2 | Haimai Medical, AccuPulse |
| 13 | Zhengxuan Investment | Venture capital firm | Shenzhen, China | 2 | 0% | 1 | Yuce Biotechnology |
| 14 | Taiyu Investment | Venture capital firm | Beijing, China | 2 | 0% | 1 | Tingsheng Technology |
| 15 | EFung Capital | Private equity firm | Shenzhen, China | 2 | 0% |
Table 3. Health care startups in Jiangsu, China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
Table 4. Health care startups in Jiangsu, China by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Health care startups in Jiangsu, China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 6. Health care startups in Jiangsu, China by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| October 2026 | 6 | 8% | $30.0M |
| September 2026 | 3 | 4% | $59.5M |
| August 2026 | 5 | 6% | $81.9M |
| July 2026 | 3 | 4% | $59.1M |
| June 2026 | 4 | 5% | $58.6M |
| May 2026 | 6 | 8% | $119.4M |
| April 2026 | 1 | 1% | $29.3M |
| March 2026 | 10 | 13% | $78.2M |
| February 2026 | 2 | 3% | $50.6M |
| January 2026 | 17 | 22% | $101.4M |
| December 2025 | 16 | 20% | $190.9M |
| November 2025 | 6 | 8% | $22.5M |
Table 7. Health care startups in Jiangsu, China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 57 | 14% | $668.0M |
| 2025 | 78 | 19% | $617.5M |
| 2024 | 55 | 13% | $339.7M |
| 2023 | 56 | 13% | $595.5M |
| 2022 | 45 | 11% | $756.1M |
| 2021 | 26 | 6% | $1.3B |
Table 8. Health care startups in Jiangsu, China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 36 | 9% |
| 2020 to 2022 | 106 | 26% |
| 2015 to 2019 | 155 | 38% |
| 2010 to 2014 | 80 | 19% |
| Before 2010 | 35 | 8% |
Table 9. Health care startups in Jiangsu, China by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 31 | 10% |
| 11 to 50 | 117 | 37% |
| 51 to 100 | 82 | 26% |
| 101 to 250 | 45 | 14% |
| 251 to 500 | 21 | 7% |
| 501 to 1,000 | 15 | 5% |
| 1,001 to 5,000 | 6 | 2% |
Table 10. Health care startups in Jiangsu, China by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Health care is one of its sectors and its headquarters is in Jiangsu, China. On 16 November 2026 that is 421 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 23 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 421 rows: 183 have no round amount, 0 no city and 150 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many health care startups in Jiangsu, China are on the list?
- 421, in the file dated 16 November 2026. 79 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 421 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.